Association of Plasma Cabozantinib Concentration With Treatment Response and Adverse Events in Japanese Patients With Advanced Renal Cell Carcinoma
This is the first clinical study to demonstrate a correlation between cabozantinib trough concentration, therapeutic efficacy, and adverse events in Japanese patients with RCC. The therapeutic drug monitoring of cabozantinib could be useful for improving therapeutic efficacy and avoiding serious adverse events.
Authors
- Tadatsugu Anno
- Tansei Sanjo
- Tatsuru Hiraga
- Masaru Kato (ORCID: https://orcid.org/0000-0002-6627-1773)
- Hiroshi Kanno (ORCID: https://orcid.org/0000-0003-3340-9462)
- Masaru Ishida
- Masashi Arai
- S. Maruyama (ORCID: https://orcid.org/0009-0008-1386-8112)
- Hiroaki Kobayashi (ORCID: https://orcid.org/0000-0003-1038-8793)
Institutions
- SHOWA Medical University (JP)
- National Defense Medical College (JP)
Publication Details
- Journal
- Therapeutic Drug Monitoring
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1097/ftd.0000000000001254
- Citations
- 1
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- Japan Society for the Promotion of Science London